| Risk | High |
|---|---|
| Min SIP Amount | ₹1000 |
| Expense Ratio | 0.76% |
| NAV | ₹10.1 (17 May 2019) |
|---|---|
| Fund Started | 25 Jun 2018 |
| Fund Size | ₹353 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 12.2% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 9.9% |
| Cipla Ltd. | Healthcare | Equity | 8.5% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 8.1% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 6.7% |
| Torrent Pharmaceuticals Ltd. | Healthcare | Equity | 6.1% |
| Lupin Ltd. | Healthcare | Equity | 4.5% |
| Biocon Ltd. | Healthcare | Equity | 4.0% |
| Dr. Lal Pathlabs Ltd. | Healthcare | Equity | 4.0% |
| Alkem Laboratories Ltd. | Healthcare | Equity | 3.8% |
Mirae Asset Mutual Fund started their mutual fund on 30/11/2007 and its managing total assets of ₹11,044 Cr. Its ranked at 22 as per total assets at end of 30th Sep 2017.
Mirae Asset is a global financial company which is present across 12 countries and 5 continents. The company was founded in 1997 and since then pioneered to become a global presence.
Mirae believes that they are the best investment choice because of their strong investment philosophy, and niche to understand comparative advantage of various companies to make a sustainable and long- lasting decision for investors. They always believe in investing with a long term goal to sustainability in the market.
They believe in assessing risk in a way that it ultimately optimizes returns of investors. They constantly monitor the valuation, liquidity and corporate governance so that any risk can be mitigated. As a global brand it has obtained the trust of investors and has made a mark for itself in the mutual fund industry.